| Serial Number | 85021938 |
| Word Mark | G |
| Filing Date | Friday, April 23, 2010 |
| Status | 710 - CANCELLED - SECTION 8 |
| Status Date | Friday, December 7, 2018 |
| Registration Number | 4133826 |
| Registration Date | Tuesday, May 1, 2012 |
| Mark Drawing | 3000 - Illustration: Drawing or design which also includes word(s) / letter(s) / number(s) |
| Published for Opposition Date | Tuesday, February 14, 2012 |
| Indication of Colors claimed | Color is not claimed as a feature of the mark. |
| Description of Mark | The mark consists of the letter "G" with a dot. |
| Goods and Services | Gene therapy systems; pharmaceutical products for the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; biological preparations for use in medical and clinical gene therapy, non-viral vectors, gene therapy vectors, nucleic acid delivery vectors, and cells transformed by viral vectors, non-viral vectors, gene therapy vectors or nucleic acid delivery vectors, all for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; biological preparations for medical and clinical use, namely, the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers; clinical medical reagents for use in nucleic acid-based therapy, gene therapy, cell therapy, gene diagnosis and gene testing; pharmaceutical preparations, namely, vaccines and prophylaxis products for use in nuclei acid-based therapy, gene therapy and cell therapy; gene and nucleic acid modulation for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, disease caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; gene therapy and prophylaxis products, namely, gene delivery and gene transfer for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone disease, inherited disorders, genetic disorders and single gene disorders; chemical reagents for clinical or medical use, namely, vectors, used in the delivery of genetic matter and nucleic acids, used in gene or nucleic acid delivery systems and used for diagnostic purposes; gene therapy and prophylaxis products, namely, gene transfer for the treatment of the prevention and treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders and single gene disorders; pharmaceutical preparations and substances for the treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, fungal diseases, diseases caused by parasites, diseases affecting the immune system, inflammatory and auto-immune diseases, vascular disorders, bone diseases, inherited disorders, genetic disorders, single gene disorders and cancers |
| Goods and Services | Medical treatment of metabolic disorders, ocular disorders, diseases of the nervous system, blood disorders, liver disorders, muscular disorders, muscular skeletal disorders, cancers, infectious diseases, inflammatory and auto-immune diseases, vascular disorders, inherited disorders, genetic disorders and single gene disorders through gene and nucleic acid delivery, gene and nucleic acid transfer, gene and nucleic acid regulation and gene and nucleic acid modulation |
| International Class | 005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides. |
| US Class Codes | 006, 018, 044, 046, 051, 052 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, December 7, 2018 |
| Primary Code | 005 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| International Class | 044 - Medical services; veterinary services; hygienic and beauty care for human beings or animals; agriculture, horticulture and forestry services. |
| US Class Codes | 100, 101 |
| Class Status Code | 2 - Sec. 8 - Entire Registration |
| Class Status Date | Friday, December 7, 2018 |
| Primary Code | 044 |
| First Use Anywhere Date | NOT AVAILABLE |
| First Use In Commerce Date | NOT AVAILABLE |
| Party Name | UNIQURE IP B.V. |
| Party Type | 31 - New Owner After Registration |
| Legal Entity Type | 99 - Other |
| Address | AMSTERDAM 1105BA NL |
| Party Name | Amsterdam Molecular Therapeutics (AMT) IP B.V. |
| Party Type | 30 - Original Registrant |
| Legal Entity Type | 99 - Other |
| Address | Amsterdam 1105BA NL |
| Party Name | Amsterdam Molecular Therapeutics (AMT) IP B.V. |
| Party Type | 20 - Owner at Publication |
| Legal Entity Type | 99 - Other |
| Address | Amsterdam 1105BA NL |
| Party Name | Amsterdam Molecular Therapeutics (AMT) IP B.V. |
| Party Type | 10 - Original Applicant |
| Legal Entity Type | 99 - Other |
| Address | Amsterdam 1105BA NL |
| Event Date | Event Description |
| Friday, December 7, 2018 | CANCELLED SEC. 8 (6-YR) |
| Monday, May 1, 2017 | COURTESY REMINDER - SEC. 8 (6-YR) E-MAILED |
| Tuesday, July 8, 2014 | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED |
| Tuesday, July 8, 2014 | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED |
| Wednesday, July 2, 2014 | AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP |
| Tuesday, May 1, 2012 | REGISTERED-PRINCIPAL REGISTER |
| Tuesday, February 14, 2012 | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED |
| Tuesday, February 14, 2012 | PUBLISHED FOR OPPOSITION |
| Wednesday, January 25, 2012 | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED |
| Tuesday, January 10, 2012 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Friday, January 6, 2012 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, January 6, 2012 | EXAMINER'S AMENDMENT ENTERED |
| Friday, January 6, 2012 | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED |
| Friday, January 6, 2012 | EXAMINERS AMENDMENT E-MAILED |
| Friday, January 6, 2012 | EXAMINERS AMENDMENT -WRITTEN |
| Thursday, January 5, 2012 | PREVIOUS ALLOWANCE COUNT WITHDRAWN |
| Tuesday, December 20, 2011 | WITHDRAWN FROM PUB - OG REVIEW QUERY |
| Tuesday, December 6, 2011 | LAW OFFICE PUBLICATION REVIEW COMPLETED |
| Monday, November 21, 2011 | APPROVED FOR PUB - PRINCIPAL REGISTER |
| Friday, November 4, 2011 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Friday, November 4, 2011 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Friday, November 4, 2011 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, May 9, 2011 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Monday, May 9, 2011 | NON-FINAL ACTION E-MAILED |
| Monday, May 9, 2011 | NON-FINAL ACTION WRITTEN |
| Wednesday, April 13, 2011 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Wednesday, April 13, 2011 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, April 13, 2011 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Friday, February 4, 2011 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Friday, February 4, 2011 | NON-FINAL ACTION E-MAILED |
| Friday, February 4, 2011 | NON-FINAL ACTION WRITTEN |
| Saturday, January 15, 2011 | TEAS/EMAIL CORRESPONDENCE ENTERED |
| Saturday, January 15, 2011 | CORRESPONDENCE RECEIVED IN LAW OFFICE |
| Wednesday, January 12, 2011 | ASSIGNED TO LIE |
| Wednesday, December 22, 2010 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Monday, December 20, 2010 | TEAS RESPONSE TO OFFICE ACTION RECEIVED |
| Wednesday, June 23, 2010 | NOTIFICATION OF NON-FINAL ACTION E-MAILED |
| Wednesday, June 23, 2010 | NON-FINAL ACTION E-MAILED |
| Wednesday, June 23, 2010 | NON-FINAL ACTION WRITTEN |
| Tuesday, June 22, 2010 | ASSIGNED TO EXAMINER |
| Friday, April 30, 2010 | NOTICE OF DESIGN SEARCH CODE MAILED |
| Thursday, April 29, 2010 | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED IN TRAM |
| Tuesday, April 27, 2010 | NEW APPLICATION ENTERED IN TRAM |